Addolorato Giovanni, Leggio Lorenzo, Abenavoli Ludovico, DeLorenzi Giosue, Parente Antonio, Caputo Fabio, Janiri Luigi, Capristo Esmeralda, Rapaccini Gian Ludovico, Gasbarrini Giovanni
Institute of Internal Medicine, Catholic University of the Sacred Heart, Gemelli Hospital, Largo A. Gemelli 8, 00168-Rome, Italy.
Clin Neuropharmacol. 2003 Sep-Oct;26(5):258-62. doi: 10.1097/00002826-200309000-00010.
Delirium tremens (DT) is a clinical condition that appears in some patients affected by severe alcohol withdrawal syndrome (AWS). DT represents a serious complication, being characterized by elevated morbidity and mortality. Benzodiazepines are presently the drug of choice; however their use is related to several side effects. Baclofen is a stereoselective gamma-aminobutyric acid (GABAB) receptor agonist. Recent studies show that baclofen is able to suppress alcohol withdrawal symptoms. At present there are no data on the effects of baclofen administration in AWS complicated by DT. Here, we report a case of DT successfully treated with baclofen. This result indicates that the efficacy of baclofen in the treatment of DT should be examined in future clinical trials.
震颤谵妄(DT)是一种出现在部分患有严重酒精戒断综合征(AWS)患者身上的临床病症。DT是一种严重并发症,其特征为发病率和死亡率升高。苯二氮䓬类药物目前是首选药物;然而其使用与多种副作用相关。巴氯芬是一种立体选择性γ-氨基丁酸(GABAB)受体激动剂。近期研究表明,巴氯芬能够抑制酒精戒断症状。目前尚无关于巴氯芬用于并发DT的AWS患者的疗效数据。在此,我们报告一例成功使用巴氯芬治疗的DT病例。这一结果表明,未来的临床试验应检验巴氯芬治疗DT的疗效。